AUTOLUS THERAPEUTICS PLC (AUTL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AUTL • US05280R1005

1.42 USD
+0.1 (+7.58%)
At close: Feb 6, 2026
1.4 USD
-0.02 (-1.41%)
Pre-Market: 2/9/2026, 7:00:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, AUTL scores 3 out of 10 in our fundamental rating. AUTL was compared to 523 industry peers in the Biotechnology industry. AUTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AUTL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AUTL had negative earnings in the past year.
  • AUTL had a negative operating cash flow in the past year.
  • In the past 5 years AUTL always reported negative net income.
  • In the past 5 years AUTL always reported negative operating cash flow.
AUTL Yearly Net Income VS EBIT VS OCF VS FCFAUTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • AUTL's Return On Assets of -33.96% is fine compared to the rest of the industry. AUTL outperforms 63.29% of its industry peers.
  • AUTL has a Return On Equity (-84.69%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.96%
ROE -84.69%
ROIC N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
AUTL Yearly ROA, ROE, ROICAUTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • AUTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AUTL Yearly Profit, Operating, Gross MarginsAUTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The debt/assets ratio for AUTL has been reduced compared to a year ago.
AUTL Yearly Shares OutstandingAUTL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
AUTL Yearly Total Debt VS Total AssetsAUTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -2.68, we must say that AUTL is in the distress zone and has some risk of bankruptcy.
  • AUTL has a Altman-Z score (-2.68) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.95 indicates that AUTL is somewhat dependend on debt financing.
  • The Debt to Equity ratio of AUTL (0.95) is worse than 74.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Altman-Z -2.68
ROIC/WACCN/A
WACC7.59%
AUTL Yearly LT Debt VS Equity VS FCFAUTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • AUTL has a Current Ratio of 6.19. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
  • AUTL's Current ratio of 6.19 is fine compared to the rest of the industry. AUTL outperforms 63.29% of its industry peers.
  • AUTL has a Quick Ratio of 5.86. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
  • AUTL's Quick ratio of 5.86 is fine compared to the rest of the industry. AUTL outperforms 62.72% of its industry peers.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 5.86
AUTL Yearly Current Assets VS Current LiabilitesAUTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.15% over the past year.
  • Looking at the last year, AUTL shows a very strong growth in Revenue. The Revenue has grown by 496.00%.
  • AUTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.31% yearly.
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.62% on average over the next years. This is quite good.
  • Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 117.77% on average per year.
EPS Next Y-15.55%
EPS Next 2Y4.21%
EPS Next 3Y10.06%
EPS Next 5Y18.62%
Revenue Next Year505.35%
Revenue Next 2Y234.18%
Revenue Next 3Y169.47%
Revenue Next 5Y117.77%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AUTL Yearly Revenue VS EstimatesAUTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
AUTL Yearly EPS VS EstimatesAUTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • AUTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUTL Price Earnings VS Forward Price EarningsAUTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUTL Per share dataAUTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.21%
EPS Next 3Y10.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AUTL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL (2/6/2026, 8:18:38 PM)

Premarket: 1.4 -0.02 (-1.41%)

1.42

+0.1 (+7.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners71.79%
Inst Owner Change0.15%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap377.92M
Revenue(TTM)51.13M
Net Income(TTM)-224.80M
Analysts85.88
Price Target9.15 (544.37%)
Short Float %5.63%
Short Ratio4.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.59%
Min EPS beat(2)-30.31%
Max EPS beat(2)25.13%
EPS beat(4)2
Avg EPS beat(4)11.3%
Min EPS beat(4)-30.31%
Max EPS beat(4)52.34%
EPS beat(8)2
Avg EPS beat(8)-51.27%
EPS beat(12)4
Avg EPS beat(12)-32.86%
EPS beat(16)6
Avg EPS beat(16)-24.54%
Revenue beat(2)1
Avg Revenue beat(2)28.11%
Min Revenue beat(2)-2.73%
Max Revenue beat(2)58.95%
Revenue beat(4)2
Avg Revenue beat(4)70.92%
Min Revenue beat(4)-99.05%
Max Revenue beat(4)326.5%
Revenue beat(8)2
Avg Revenue beat(8)-9.59%
Revenue beat(12)4
Avg Revenue beat(12)7.38%
Revenue beat(16)5
Avg Revenue beat(16)97.39%
PT rev (1m)-2.18%
PT rev (3m)-5.18%
EPS NQ rev (1m)-5.29%
EPS NQ rev (3m)-16.99%
EPS NY rev (1m)-2.07%
EPS NY rev (3m)-14%
Revenue NQ rev (1m)2.28%
Revenue NQ rev (3m)-6.54%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)3.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.39
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.19
BVpS1
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.96%
ROE -84.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 560.18%
Cap/Sales 101.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.19
Quick Ratio 5.86
Altman-Z -2.68
F-Score2
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)254.9%
Cap/Depr(5y)225.76%
Cap/Sales(3y)387.17%
Cap/Sales(5y)479.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
EPS Next Y-15.55%
EPS Next 2Y4.21%
EPS Next 3Y10.06%
EPS Next 5Y18.62%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
Revenue Next Year505.35%
Revenue Next 2Y234.18%
Revenue Next 3Y169.47%
Revenue Next 5Y117.77%
EBIT growth 1Y-37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.78%
EBIT Next 3Y9.29%
EBIT Next 5Y23.74%
FCF growth 1Y-110.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.84%
OCF growth 3YN/A
OCF growth 5YN/A

AUTOLUS THERAPEUTICS PLC / AUTL FAQ

What is the fundamental rating for AUTL stock?

ChartMill assigns a fundamental rating of 3 / 10 to AUTL.


What is the valuation status of AUTOLUS THERAPEUTICS PLC (AUTL) stock?

ChartMill assigns a valuation rating of 0 / 10 to AUTOLUS THERAPEUTICS PLC (AUTL). This can be considered as Overvalued.


How profitable is AUTOLUS THERAPEUTICS PLC (AUTL) stock?

AUTOLUS THERAPEUTICS PLC (AUTL) has a profitability rating of 1 / 10.


Can you provide the financial health for AUTL stock?

The financial health rating of AUTOLUS THERAPEUTICS PLC (AUTL) is 4 / 10.


What is the earnings growth outlook for AUTOLUS THERAPEUTICS PLC?

The Earnings per Share (EPS) of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to decline by -15.55% in the next year.